



Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

Item 8.01 Other Events

On December 15, 2017, Kyowa Hakko Kirin Co., Ltd., Kyowa Kirin International PLC and Ultragenyx Pharmaceutical Inc. (the “Company”) issued a joint press release (the “Release”) announcing that the Committee for Medicinal Products for Human Use, the European Medicine Agency’s scientific committee, has adopted a Positive Opinion recommending the conditional marketing authorization of burosumab for the treatment of X-linked hypophosphatemia in children.

A copy of the Release is filed herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description

99.1 Press Release, dated December 15, 2017

\*\*\*

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 15, 2017

Ultragenyx Pharmaceutical Inc.

By: /s/ Shalini Sharp

Name: Shalini Sharp

Title: Executive Vice President, Chief Financial

Officer